This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.63% per year. These returns cover a period from January 1, 1988 through December 2, 2019. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
GSK or ACAD: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
GSK vs. ACAD: Which Stock Is the Better Value Option?
ACAD Stock Soars as US Court Rules in Favor of Key Nuplazid Patent
by Zacks Equity Research
Acadia stock jumps 27% after winning a key patent case for Nuplazid, which will protect the drug's U.S. sales from generic erosion till 2038.
Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings and Revenue Estimates (Revised)
by Zacks Equity Research
Acadia (ACAD) delivered earnings and revenue surprises of 10% and 1.23%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Acadia Q1 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth
by Zacks Equity Research
ACAD reports encouraging first-quarter results as earnings and revenues beat estimates, driven by year-over-year growth in Nuplazid and Daybue sales.
Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Acadia (ACAD) delivered earnings and revenue surprises of 10% and 1.23%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
DENTSPLY SIRONA to Post Q1 Earnings: What's in Store for the Stock?
by Zacks Equity Research
XRAY is likely to have faced a tough first quarter with Byte's revenue loss, weak U.S. equipment demands and implant pressures.
Analysts Estimate Fortrea Holdings Inc. (FTRE) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Fortrea Holdings Inc. (FTRE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates
by Ahan Chakraborty
Let us look at some drug/biotech stocks, NVO, PCRX, RARE, ACAD and DNLI, which are poised to beat on first-quarter 2025 earnings.
Earnings Preview: Acadia Pharmaceuticals (ACAD) Q1 Earnings Expected to Decline
by Zacks Equity Research
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Acadia (ACAD) Stock Jumps 6.1%: Will It Continue to Soar?
by Zacks Equity Research
Acadia (ACAD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Why Is Acadia (ACAD) Down 11.1% Since Last Earnings Report?
by Zacks Equity Research
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug
by Zacks Equity Research
Soleno's shares soar in the premarket hours following the FDA approval of Vykat XR (diazoxide choline) for treating hyperphagia in PWS patients.
Will Auvelity & Other Drugs Aid AXSM's Growth Amid Stiff Competition?
by Zacks Equity Research
Axsome's depression drug, Auvelity, is driving the top line while Sunosi diversifies its business. The recent FDA nod for Symbravo also bodes well.
Acadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates (Revised)
by Zacks Equity Research
Acadia (ACAD) delivered earnings and revenue surprises of -10.53% and 1.79%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Acadia's Q4 Earnings Miss, Nuplazid & Daybue Drive Revenue Growth (Revised)
by Zacks Equity Research
ACAD reports mixed fourth-quarter results as earnings missed estimates while revenues beat the same, driven by year-over-year growth in Nuplazid and Daybue sales.
Acadia's Q4 Earnings Miss, Nuplazid & Daybue Drive Revenue Growth
by Zacks Equity Research
ACAD reports mixed fourth-quarter results as earnings missed estimates while revenues beat the same, driven by year-over-year growth in Nuplazid and Daybue sales.
Acadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates
by Zacks Equity Research
Acadia (ACAD) delivered earnings and revenue surprises of -10.53% and 1.79%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Is the Options Market Predicting a Spike in ACADIA Pharmaceuticals (ACAD) Stock?
by Zacks Equity Research
Investors need to pay close attention to ACADIA Pharmaceuticals (ACAD) stock based on the movements in the options market lately.
Blueprint Medicines (BPMC) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Blueprint Medicines (BPMC) delivered earnings and revenue surprises of -12.86% and 0.79%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
by Zacks Equity Research
Sector ETF report for FBT
ACAD Seeks EU Nod for Rett Syndrome Drug, Outlines 2025 Pipeline Goals (Revised)
by Zacks Equity Research
Acadia files regulatory application for trofinetide to treat Rett syndrome in EU. The company also outlines other pipeline goals for 2025-2026.
ACAD Seeks EU Nod for Rett Syndrome Drug, Outlines 2025 Pipeline Goals
by Zacks Equity Research
Acadia files regulatory application for trofinetide to treat Rett syndrome in EU. The company also outlines other pipeline goals for 2025-2026.
Here's Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Acadia (ACAD) Down 2.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.